• Skip to main content
  • Skip to secondary menu
  • Skip to primary sidebar
  • Skip to secondary sidebar
  • Skip to footer

  • Opinion
  • Health IT
    • Behavioral Health
    • Care Coordination
    • EMR/EHR
    • Interoperability
    • Patient Engagement
    • Population Health Management
    • Revenue Cycle Management
    • Social Determinants of Health
  • Digital Health
    • AI
    • Blockchain
    • Precision Medicine
    • Telehealth
    • Wearables
  • Life Sciences
  • Investments
  • M&A
  • Value-based Care
    • Accountable Care (ACOs)
    • Medicare Advantage

NVIDIA Makes Drug Discovery, Medical Imaging, and Genomics Easier with Cloud-Based AI

by Fred Pennic 05/03/2024 Leave a Comment

  • LinkedIn
  • Twitter
  • Facebook
  • Email
  • Print

What You Should Know:

– Harnessing the power of AI for healthcare just got simpler. NVIDIA announced the integration of NVIDIA NIM, a collection of cloud-native AI microservices, with Amazon Web Services (AWS). 

– The strategic collaboration empowers developers to leverage pre-trained AI models for drug discovery, medical imaging analysis, and genomics research – all accessible through user-friendly APIs.

Streamlined Access to Powerful AI Tools

NIM integrates seamlessly with popular AWS services like SageMaker (for machine learning model development) and ParallelCluster (for high-performance computing). Additionally, AWS HealthOmics, a specialized service for biological data analysis, can orchestrate NIM workflows. This integration simplifies the process of deploying cutting-edge AI models for healthcare and life sciences companies already using the AWS cloud infrastructure.

Benefits of NVIDIA NIM on AWS

  • Faster Development: Researchers can bypass complex model development and packaging, accelerating the deployment of generative AI solutions.
  • Multimodal Workflows: NIM facilitates the creation of workflows combining AI models from various sources, like protein sequences, medical images, and patient records.
  • Enhanced Drug Discovery: BioNeMo, a foundation for AI models in drug discovery, is included in NIM. Companies like Amgen are already utilizing BioNeMo to train protein design models.

Real-World Examples of Success

  • A-Alpha Bio: This company developing protein interaction prediction tools saw a 10x speedup by utilizing BioNeMo models optimized for NVIDIA GPUs on AWS.
  • Agilent: This life sciences leader used NVIDIA Parabricks, a genomics analysis tool within NIM, to significantly improve processing speeds for variant calling workflows.

Beyond Drug Discovery and Genomics

NIM offers more than just scientific applications. It also includes:

  • Large Language Models: These powerful language processing tools can be used to create conversational AI healthcare assistants for patient education and clinician support.
  • Visual Generative AI: This technology allows for the development of digital avatars and chatbots for a more engaging user experience.
  • LinkedIn
  • Twitter
  • Facebook
  • Email
  • Print

Tagged With: Artificial Intelligence

Tap Native

Get in-depth healthcare technology analysis and commentary delivered straight to your email weekly

Reader Interactions

Primary Sidebar

Subscribe to HIT Consultant

Latest insightful articles delivered straight to your inbox weekly.

Submit a Tip or Pitch

Featured Insights

Aligning IT & Clinical Teams: How to Reduce Friction and Improve Communication

Most-Read

M&A: Tempus AI to Acquire Personalis for $1.5B to Expand Precision Oncology and MRD Monitoring

M&A: Tempus AI to Acquire Personalis for $1.5B to Expand Precision Oncology and MRD Monitoring

Why Brain Health Is Entering Its Infrastructure Era

Brain Health’s Infrastructure Era: Proving Clinical Outcomes with Integrated Neuromotor Tracking

Why Catholic Health Inked a $500M Care Alliance with GE HealthCare to Automate Outpatient Triage

Catholic Health Inks $500M Care Alliance with GE HealthCare to Automate Outpatient Triage

KLAS Global HIT Trends 2026 Report: Artificial Intelligence Becomes the Top Investment Priority

KLAS Global HIT Trends 2026 Report: Artificial Intelligence Becomes the Top Investment Priority

Optum Partners with Anthropic to Deploy Claude Across Healthcare Claims and Revenue Workflows

Optum Partners with Anthropic to Deploy Claude Across Healthcare Claims and Revenue Workflows

Rock Health H1 2026 Digital Health Funding Recap: Startups Hit $7.4B in Venture Rebound

Rock Health H1 2026 Digital Health Funding Recap: Startups Hit $7.4B in Venture Rebound

M&A: ResMed to Sell MatrixCare Business to Frazier Healthcare Partners for $450M

M&A: ResMed to Sell MatrixCare Business to Frazier Healthcare Partners for $450M

The Real Risk in Healthcare AI Isn’t the Model. It’s the Data. 

Clinical Data Fidelity: The Real Blindspot in Healthcare AI Strategy

KLAS 2026 EHR Market Share Report: Epic Gains as Oracle Health Faces Third Year of Losses

KLAS 2026 EHR Market Share Report: Epic Gains as Oracle Health Faces Third Year of Losses

Qualtrics Acquires Press Ganey Forsta for $6.75B to Create the Most Comprehensive AI Experience Platform

M&A: Qualtrics Completes $6.75B Acquisition of Press Ganey Forsta

Secondary Sidebar

Footer

Company

  • About Us
  • 2026 Editorial Calendar
  • Advertise with Us
  • Reprints and Permissions
  • Op-Ed Submission Guidelines
  • Contact
  • Subscribe

Editorial Coverage

  • Opinion
  • Health IT
    • Care Coordination
    • EMR/EHR
    • Interoperability
    • Population Health Management
    • Revenue Cycle Management
  • Digital Health
    • Artificial Intelligence
    • Blockchain Tech
    • Precision Medicine
    • Telehealth
    • Wearables
  • Startups
  • Value-Based Care
    • Accountable Care
    • Medicare Advantage

Connect

Subscribe to HIT Consultant Media

Latest insightful articles delivered straight to your inbox weekly

Copyright © 2026. HIT Consultant Media. All Rights Reserved. Privacy Policy |